Immunic
IMUX
58 hedge funds and large institutions have $34.8M invested in Immunic in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 22 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
42% more call options, than puts
Call options by funds: $738K | Put options by funds: $521K
0.1% less ownership
Funds ownership: 5.71% → 5.61% (-0.1%)
11% less funds holding
Funds holding: 65 → 58 (-7)
18% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 22
37% less capital invested
Capital invested by funds: $55.1M → $34.8M (-$20.3M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$3.13M |
| 2 |
RI
RTW Investments
New York
|
+$3M |
| 3 |
GC
Gratus Capital
Atlanta,
Georgia
|
+$2.5M |
| 4 |
CC
Commodore Capital
New York
|
+$2.47M |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$3.39M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.66M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.35M |
| 4 |
Millennium Management
New York
|
-$1.3M |
| 5 |
CAC
Cowen and Company
New York
|
-$1.12M |
IMUX Hedge Fund Activity: Q4 2022 in Review
58 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2022, worth a combined $34.8M — down 37% from $55.1M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of IMUX and 18 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 24 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $3.13M. The largest seller was Lynx1 Capital Management, exiting entirely with an estimated $3.39M sold.
- 58 institutional investors held Immunic (IMUX) as of Q4 2022, down from 65 in Q3 2022.
- Funds reported $34.8M of Immunic stock for Q4 2022, down 37% quarter-over-quarter.
- 18 funds opened new Immunic positions in Q4 2022 and 22 closed out, a net change of -4 holders.
- The largest Immunic buyer in Q4 2022 was BVF Inc, an estimated $3.13M added.
- The largest Immunic seller in Q4 2022 was Lynx1 Capital Management, an estimated $3.39M sold.
Based on aggregated 13F filings for Q4 2022.